Malignant Mesothelioma
📧 Sign up to get email alerts when something new happens for Malignant Mesothelioma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS withdrawal · 2026-03-17Clinical Trial Update: Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma [Phase 2]
Phase 2 trial of APG-115 (Alrizomadlin) for BAP1 tumor predisposition syndrome with mesothelioma has been withdrawn.
-
EMA withdrawal · 2024-11-06EMA Withdrawn: Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) — Sandoz GmbH
The European Medicines Agency has withdrawn Pemetrexed Sandoz (pemetrexed disodium hemipentahydrate) from the European market. It was indica…
-
EMA withdrawal · 2024-10-17EMA Withdrawn: Ciambra (pemetrexed disodium hemipentahydrate) — Menarini International Operations Luxembourg S.A.
EMA withdrew Ciambra (pemetrexed disodium hemipentahydrate) from the European market on 17 August 2022, with indications for non-small cell …
-
EMA withdrawal · 2024-07-30EMA Withdrawn: Pemetrexed Krka (pemetrexed disodium) — KRKA d.d.
EMA has withdrawn the product Pemetrexed Krka (pemetrexed disodium) from the market.
-
CLINICAL_TRIALS withdrawal · 2015-12-15Clinical Trial Update: Comparison of Progel Sealant to Standard of Care (SOC) for Patients Undergoing Decortication [Phase 3]
A Phase 3 trial comparing Progel Sealant to standard of care for patients undergoing decortication has been withdrawn.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS withdrawal · 2015-10-02Clinical Trial Update: Optical Coherence Tomography of the Airway for Lung Cancer or Lung Disease
Clinical trial NCT00733252 investigating optical coherence tomography of the airway for lung cancer or lung disease has been withdrawn.
-
CLINICAL_TRIALS withdrawal · 2014-05-21Clinical Trial Update: A Study of VEGF-Antisense Oligonucleotide in Combination With Pemetrexed and Cisplatin for the Treatment of Advanced Malignant Mesothelioma [Phase 1, Phase 2]
A Phase 1/2 trial evaluating a VEGF-Antisense Oligonucleotide in combination with pemetrexed and cisplatin for advanced malignant mesothelio…
-
CLINICAL_TRIALS withdrawal · 2013-08-02Clinical Trial Update: AMG 102, Pemetrexed Disodium, and Cisplatin in Treating Patients With Malignant Pleural Mesothelioma [Phase 2]
Phase 2 trial evaluating AMG 102 in combination with pemetrexed disodium and cisplatin for malignant pleural mesothelioma has been withdrawn…